65.05
1.15 (1.80%)
| Penutupan Terdahulu | 63.90 |
| Buka | 65.00 |
| Jumlah Dagangan | 627,126 |
| Purata Dagangan (3B) | 1,865,274 |
| Modal Pasaran | 6,049,188,864 |
| Harga / Pendapatan (P/E Ke hadapan) | 76.34 |
| Harga / Jualan (P/S) | 9.58 |
| Harga / Buku (P/B) | 238.82 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 29 Oct 2026 |
| Margin Keuntungan | -82.88% |
| Margin Operasi (TTM) | -52.21% |
| EPS Cair (TTM) | -2.78 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 97.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1,220.07% |
| Nisbah Semasa (MRQ) | 2.05 |
| Aliran Tunai Operasi (OCF TTM) | -160.66 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -239.23 M |
| Pulangan Atas Aset (ROA TTM) | -23.21% |
| Pulangan Atas Ekuiti (ROE TTM) | -422.66% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Travere Therapeutics, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | 2.0 |
| Purata | -0.67 |
|
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 0.75% |
| % Dimiliki oleh Institusi | 113.30% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |